Sasaki, K., Jabbour, E. J., Ravandi, F., Short, N. J., Thomas, D. A., Garcia‐Manero, G., Daver, N. G., Kadia, T. M., Konopleva, M. Y., Jain, N., Issa, G. C., Jeanis, V., Moore, H. G., Garris, R. S., Pemmaraju, N., Cortes, J. E., O'Brien, S. M., & Kantarjian, H. M. (2016). hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 122(23), 3650–3656. http://access.bl.uk/ark:/81055/vdc_100039242094.0x000064